C25023: Effectiveness and Safety for Re-treatment with Brentuximab-Vedotin (BV) in Patients with Relapsed/Refractory (R/R) CD30+ malignancies: a retrospective medical chart review study in Spain. The BELIEVE Study.

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  The data will be collected by hematologist/oncologist from the medical record of participants will be recorded in electronic case report forms (e-CRFs).

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No